Articles by Michael Schwitter
109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR
ByDiana I. Lüftner,Rupert Bartsch,Urs Breitenstein,Christian Jackisch,Volkmar Mueller,Marcus Schmidt,Marija Balic,Gabriel Rinnerthaler,Khalil Zaman,Michael Schwitter,Denise Wrobel,Dagmar Guth,Matthias Zaiss,Jürgen Terhaag,Lidia Perlova-Griff,Rachel Wuerstlein,Timo Schinköthe,Corinne Vannier,Nadia Harbeck, MD, PhD 
106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)
ByReshma L. Mahtani, DO ,Diana Lüftner,Denise Wrobel,Dagmar Guth,Matthias Zaiss,Jürgen Terhaag,Mark-Oliver Zahn,Lidia Pervola-Griff,Andrea Distelrath,Rachel Würstlein,Jörg Thomalla,Klaus Apel,Natalija Deuerling,Timo Schinköthe,Corinne Vannier,Rupert Bartsch,Christian Jackisch,Volkmar Müller,Marcus Schmidt,Marija Balic,Gabriel Rinnerthaler,Urs Breitenstein,Khalil Zaman,Michael Schwitter,Nadia Harbeck, MD, PhD
